Skip to main content
. Author manuscript; available in PMC: 2015 Jan 20.
Published in final edited form as: Diabetes. 2007 Feb 7;56(5):1341–1349. doi: 10.2337/db06-1619

TABLE 3.

Ceramide and glycosphingolipid levels in liver of normal and ZDF rats treated with AMP-DNM

Liver sphingolipid
(nmol/g wet wt)		 0 mg AMP-DNM
· kg−1 · day−1 		5 mg AMP-DNM
· kg−1 · day−1 		25 mg AMP-DNM
· kg−1 · day−1 		Normal
littermate
Ceramide 461 ± 29 416 ± 24 451 ± 37 475 ± 25
Glucosylceramide 56.7 ± 9.2 53.4 ± 5.7 47.4 ± 5.2 46.1 ± 5.0
Gangliosides
 GM3 22.5 ± 3.2 21.3 ± 2.9 17.3 ± 2.7 20.0 ± 2.2
 GM2 6.2 ± 1.0 5.9 ± 0.9 4.8 ± 0.8 5.0 ± 0.4
 GM1 11.6 ± 2.9 11.4 ± 2.2 5.6 ± 1.1 9.1 ± 1.5
GDA1 15.7 ± 1.5 15.5 ± 1.7 7.9 ± 0.9 16.4 ± 1.2

Data are means ± SD. Animals were fed for 10 weeks with 0, 5, or 25 mg AMP-DNM/kg. Liver was collected and analyzed on ceramide, glucosylceramide, and ganglioside content.